Home

Amphastar Pharmaceuticals, Inc. - Common Stock (AMPH)

23.20
-0.25 (-1.07%)
NASDAQ · Last Trade: Jun 26th, 2:59 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
3 Value Stocks with Questionable Fundamentals
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
Via StockStory · June 24, 2025
AMPHASTAR PHARMACEUTICALS INC (NASDAQ:AMPH) – An Undervalued Stock Worth Consideringchartmill.com
AMPH ASTAR PHARMACEUTICALS INC (NASDAQ:AMPH) is an undervalued stock with strong profitability, reasonable financial health, and an attractive valuation, making it a candidate for value investors.
Via Chartmill · June 12, 2025
3 Russell 2000 Stocks with Questionable Fundamentals
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.
Via StockStory · June 11, 2025
3 Small-Cap Stocks Walking a Fine Line
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.
Via StockStory · May 29, 2025
Earnings Scheduled For May 7, 2025benzinga.com
Via Benzinga · May 7, 2025
Earnings Outlook For Amphastar Pharmabenzinga.com
Via Benzinga · May 6, 2025
Earnings Scheduled For February 27, 2025benzinga.com
Via Benzinga · February 27, 2025
Evolent Health, Amphastar Pharmaceuticals, Iridium, and Magnite Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +2.0%, S&P 500 +2.0%) as President Trump postponed the planned 50% tariff on European Union imports, shifting the start date to July 9, 2025. 
Via StockStory · May 27, 2025
Generic Pharmaceuticals Stocks Q1 In Review: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs Peers
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers.
Via StockStory · May 22, 2025
AMPHASTAR PHARMACEUTICALS INC (NASDAQ:AMPH) – A Potentially Undervalued Stock Worth Watchingchartmill.com
AMPH ASTAR PHARMACEUTICALS INC (NASDAQ:AMPH) offers strong profitability and an undervalued stock price, making it a candidate for value investors. Check the full analysis for details.
Via Chartmill · May 17, 2025
This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Mondaybenzinga.com
Via Benzinga · May 12, 2025
Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q1 Sales Targets
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $170.5 million. Its non-GAAP profit of $0.74 per share was 7.6% above analysts’ consensus estimates.
Via StockStory · May 7, 2025
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH): A Closer Look at Dividend Potentialchartmill.com
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH): A Closer Look at Dividend Potential
Via Chartmill · May 1, 2025
2 Healthcare Stocks on Our Watchlist and 1 to Be Wary Of
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 10.9%. This performance was worse than the S&P 500’s 5.6% decline.
Via StockStory · April 29, 2025
Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest
Let’s dig into the relative performance of Viatris (NASDAQ:VTRS) and its peers as we unravel the now-completed Q4 generic pharmaceuticals earnings season.
Via StockStory · April 28, 2025
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) is an undervalued gem with solid fundamentals.chartmill.com
Uncover the potential of AMPHASTAR PHARMACEUTICALS IN, an undervalued stock. NASDAQ:AMPH maintains a strong financial position and offers an appealing valuation.
Via Chartmill · April 25, 2025
2 Safe-and-Steady Stocks with Solid Fundamentals and 1 to Think Twice About
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Via StockStory · April 24, 2025
2 Reasons to Like AMPH and 1 to Stay Skeptical
What a brutal six months it’s been for Amphastar Pharmaceuticals. The stock has dropped 50.3% and now trades at $24.50, rattling many shareholders. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.
Via StockStory · April 15, 2025
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH), an undervalued stock with good fundamentals.chartmill.com
Take a closer look at AMPHASTAR PHARMACEUTICALS IN , a remarkable value stock. NASDAQ:AMPH excels in fundamentals and maintains a very reasonable valuation.
Via Chartmill · March 27, 2025
Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at generic pharmaceuticals stocks, starting with Amphastar Pharmaceuticals (NASDAQ:AMPH).
Via StockStory · March 13, 2025
Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers.
Via StockStory · March 5, 2025
Amphastar: Earnings Miss, Margins Dropfool.com
Amphastar Pharmaceuticals posted modest earnings growth but fell short of market expectations in its latest quarterly results.
Via The Motley Fool · February 28, 2025
Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwindsbenzinga.com
Amphastar's Q4 sales grew 20% to $186.5M, missing estimates. Primatene MIST surpassed $100M in annual sales, while Baqsimi saw strong growth.
Via Benzinga · February 28, 2025
Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q4 Sales Targets, Stock Drops 12.1%
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) missed Wall Street’s revenue expectations in Q4 CY2024 as sales rose 4.7% year on year to $186.5 million. Its non-GAAP profit of $0.92 per share was 1.9% below analysts’ consensus estimates.
Via StockStory · February 27, 2025
Earnings To Watch: Amphastar Pharmaceuticals (AMPH) Reports Q4 Results Tomorrow
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting earnings tomorrow after market hours. Here’s what to expect.
Via StockStory · February 26, 2025